Lyell Immunopharma Inc
LYEL13.090USD
+0.450+3.56%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
194.14MMarket Cap
LossP/E TTM
More Details of Lyell Immunopharma Inc Company
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company advancing a pipeline of product candidates enhanced with its proprietary anti-exhaustion technologies for patients with solid tumors or hematologic malignancies. The Company's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to resist exhaustion and kill cancer cells. Its technologies are designed to generate T cells with the ability to persist and self-renew while driving tumor cytotoxicity. Its two product candidates, LYL797 and LYL845, are in Phase I clinical development, and an additional product candidate, LYL119, is entering Phase I clinical development. The Company is also engaged in accelerating the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma.
Company Info
Ticker SymbolLYEL
Company nameLyell Immunopharma Inc
IPO dateJun 17, 2021
CEODr. Lynn Seely, M.D.
Number of employees300
Security typeOrdinary Share
Fiscal year-endJun 17
Address201 Haskins Way
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16506950677
Websitehttps://lyell.com/
Ticker SymbolLYEL
IPO dateJun 17, 2021
CEODr. Lynn Seely, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.70K
+365.10%
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
1.78K
--
Dr. Mark Bachleda
Dr. Mark Bachleda
Director
Director
--
--
Mr. Charles Newton
Mr. Charles Newton
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Richard D. Klausner, M.D.
Dr. Richard D. Klausner, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Stephen Hill
Mr. Stephen Hill
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William J. (Bill) Rieflin
Mr. William J. (Bill) Rieflin
Independent Director
Independent Director
--
--
Dr. Gary Lee, Ph.D.
Dr. Gary Lee, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.70K
+365.10%
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
1.78K
--
Dr. Mark Bachleda
Dr. Mark Bachleda
Director
Director
--
--
Mr. Charles Newton
Mr. Charles Newton
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Richard D. Klausner, M.D.
Dr. Richard D. Klausner, M.D.
Chairman of the Board
Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARCH Venture Partners
9.48%
GSK plc
7.87%
Foresite Capital Management, LLC
6.28%
Gates Frontier, L.L.C.
5.42%
Explore Investments LLC
5.42%
Other
65.53%
Shareholders
Shareholders
Proportion
ARCH Venture Partners
9.48%
GSK plc
7.87%
Foresite Capital Management, LLC
6.28%
Gates Frontier, L.L.C.
5.42%
Explore Investments LLC
5.42%
Other
65.53%
Shareholder Types
Shareholders
Proportion
Investment Advisor
21.27%
Corporation
18.93%
Venture Capital
14.32%
Private Equity
9.02%
Hedge Fund
3.51%
Individual Investor
1.64%
Investment Advisor/Hedge Fund
1.43%
Research Firm
0.23%
Pension Fund
0.15%
Other
29.50%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
273
11.42M
73.88%
-621.28K
2025Q1
284
16.50M
76.82%
-316.09K
2024Q4
285
234.38M
80.23%
+17.13M
2024Q3
284
205.56M
78.25%
-10.65M
2024Q2
276
225.77M
86.93%
-4.87M
2024Q1
265
225.53M
87.01%
-3.27M
2023Q4
256
223.66M
89.04%
+190.31K
2023Q3
246
214.93M
85.87%
-13.13M
2023Q2
244
214.42M
85.94%
-10.26M
2023Q1
230
210.61M
84.42%
-12.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARCH Venture Partners
1.82M
11.8%
--
--
Dec 31, 2024
GSK plc
1.51M
9.8%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
1.21M
7.82%
+384.15K
+46.68%
Mar 31, 2025
MWG Management, Ltd.
1.01M
6.53%
--
--
Mar 31, 2025
Orland Properties Ltd
754.70K
4.89%
--
--
Mar 31, 2025
Decheng Capital LLC
595.47K
3.86%
--
--
Mar 31, 2025
Almitas Capital LLC
124.13K
0.8%
+71.60K
+136.32%
Mar 31, 2025
VenBio Partners LLC
355.11K
2.3%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
